The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 801–900 of 958
Warum ist dauerhaft abnehmen so schwer?
Özcan, Ö., & Kern, W. (2018) · CardioVasc · doi:10.1007/s15027-018-1366-3 · Cited by 1
Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases
Abe, T. K., Nakanishi, M., Watanabe, O., Kawano, H., & Bando, H. (2018) · Diabetes Research - Open Journal · doi:10.17140/droj-4-136
Effect of Liraglutide on Weight Reduction in Euthyroid, Non Diabetic Obese Patients
Kashiva, R. T. (2019) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000204
Physiology of obesity and metabolism
Chu, J. J., & Mehrzad, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90965-5.00004-0 · Cited by 1
How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes
Pedersen, S. D. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.115 · Cited by 1
Coppola, T., Daziano, G., Legroux, I., Béraud-Dufour, S., Blondeau, N., & Lebrun, P. (2023) · Cells · doi:10.3390/cells12232768 · Cited by 1
“GLP-1 is present in the brain [76] and is involved in the regulation of food intake in the hypothalamus and reward areas [77].”
BackgroundChianelli, M., Albanese, A., Carabotti, M., Casarotto, D., Pergola, G. D., Disoteo, O., Grandone, I., Medea, G., Nisoli, E., Raffaelli, M., et al. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01417-8 · Cited by 3
“Recettori centrali del GLP-1 sono localizzati anche nel-l’area meso-limbica, nell’area tegmentale ventrale e nel nucleo accumbens : in questo modo liraglutide influenza anche il circuito meso-limbico di gratificazione [110].”
Chirayath, S., Dauleh, H., Pasha, M., Ismail, F., & Hussain, K. (2024) · Annals of Case Reports · doi:10.29011/2574-7754.101594
Novel therapeutic strategy for obesity through the gut microbiota-brain axis: A review article.
Kardan, R., Hemmati, J., Nazari, M., Ahmadi, A., Asghari, B., Azizi, M., Khaledi, M., & Arabestani, M. R. (2024) · PubMed Central · doi:10.22088/cjim.15.2.215 · Cited by 5
“In addition GLP-1RAs activate and suppresses POMC/CART and POMC/CART neurons, respectively, which induces satiety and thus weight loss (83).”
BackgroundWang, W., Yang, Y.-Z., Xing, Y., Zhou, Z.-A., Jiang, Q.-Y., Huang, L., Kong, L., & Zhang, D. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156242 · Cited by 1
Yu, H., Feng, N., Zhong, W., Han, Y., Cheng, Y., Zhang, Z., Wang, Y., Gao, P., Huang, R., Zhang, C., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402546r · Cited by 2
“To further confirm the effects of liraglutide on food intake and obesity is independent of ARC and PVN neurons, liraglutide was injected into Syn1-Cre mice once a day 12 days after bilateral injection of AAV- EF1a- flex- taCasp3-TEVp once into ARC or PVN.”
InfluentialAdvancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
“Notably, two GLP1RAs, liraglutide and semaglutide, have been shown to access the area postrema, subfornical organ and median eminence; by contrast, the ability of dulaglutide and albiglutide, which are relatively large molecules, to access to these regions may be limited (37,38).”
Gmoshinski, I. V., Apryatin, S. A., KhKh, S., Nikityuk, D. B., & Tutelyan, V. A. (2018) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn973 · Cited by 2
The Gastrointestinal System and Obesity
Calderón, G., & Acosta, A. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814468-8.00004-1 · Cited by 3
Short term effects of experimental gastric outlet obstruction and truncal vagotomy on gut hormones
Öztürk, A. S., Aydin, M., Bozkurt, Y. A., Küçükgül, A., & Öztürk, A. (2021) · Biotechnic & Histochemistry · doi:10.1080/10520295.2021.1896780 · Cited by 1
“Activation of NPY enhances food intake (Secher et al. 2014).”
Hypothalamic Inflammation and Hypothalamic Obesity: Case Report and Mini-Review
Fjalldal, S. B., Stenberg, L., Gabery, S., Karlsson, S., & Erfurth, E. M. (2022) · Journal of Endocrinological Science · doi:10.29245/2767-5157/2022/1.1121 · Cited by 1
Bakker, W., Salinas, C. G., Imbernón, M., Chao, D. H. M., Hassouna, R., Morel, C., Martin, C., Gangarossa, G., Denis, R., Castel, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.11.198341 · Cited by 1
Self-citationNeuroanatomical dissection of the MC3R circuitry regulating energy rheostasisPreprint
Possa‐Paranhos, I. C., Butts, J., Pyszka, E., Nelson, C., Cho, D., & Sweeney, P. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.22.590573 · Cited by 1
German, J., Cordioli, M., Tozzo, V., Urbut, S., Arumäe, K., Smit, R. A. J., Lee, J., Li, J. H., Janucik, A., Ding, Y., et al. (2024) · medRxiv · doi:10.1101/2024.09.11.24313458 · Cited by 1
Females are protected from semaglutide-induced muscle loss in ob/ob micePreprint
Rout, S., Karasawa, T., Watanabe, S., Chaix, A., Drummond, M. J., Funai, K., & Choi, R. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.709376 · Cited by 1
On the Impact of Bariatric Surgery on Glucose Homeostasis
Abrahamsson, N. (2016) · Uppsala University Publications (Uppsala University)
Gewichtssenkende Medikamente in der Diabetologie
Aberle, J. (2015) · Der Diabetologe · doi:10.1007/s11428-015-0004-2
“Entsprechende Daten aus Mausmodellen liegen für Liraglutid vor [21].”
BackgroundIncretin hormones as a target for therapy
Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2
Pharmacological management of obesity in patients with type 2 diabetes
Black, R. L., Higbea, A. M., Duval, C., & Chastain, L. M. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1220300 · Cited by 1
“central nervous system resulting in appetite suppression [41].”
BackgroundToyoda, M., Miyauchi, M., Kaneyama, N., Kimura, M., Umezono, T., Suzuki, D., & Fukagawa, M. (2017) · Journal of Diabetes and Obesity · doi:10.15436/2376-0494.17.1300
Besserung der Komorbidität – Liraglutid 3,0 mg bei Patienten mit Adipositas
Aberle, J. (2017) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0037-1618955
“Die zugrundeliegenden Mechanismen bleiben bisher unklar (22).”
BackgroundJang, M., Park, S., Kim, Y.-W., Jung, S.-P., & Kim, J.-Y. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.3.225
“Considering that GLP-1 reduces food intake by directly stimulating POMC/cocaine and amphetamine regulated transcript (CART) neurons [11,12], there is a discrepancy with our findings and previous studies [11,12] in that CHO-rich Response”
BackgroundResultKoo, B. K. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.3.223
“Along with POMC stimulation, GLP-1 can also affect NPY; it indirectly inhibits neurons expressing NPY and agouti-related peptide (AgRP) via γ-aminobutyric acid (GABA)-dependent signaling [6,7].”
BackgroundResultAdipositas und Prädiabetes: Therapie mit GLP‑1 Rezeptoragonisten
Ritzel, R. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0274-y
“Eine Wirkung direkt am oder über das Zentralnervensystem spielt dabei eine wichtige Rolle [6, 15].”
BackgroundTHE ROLE OF THE INTESTINAL MICROBIOTA IN THE MODULATION OF FOOD INTAKE AND BODY WEIGHTPreprint
Dalby, M. J. (2017) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/rqz2p
Liraglutid in der Pharmakotherapie der Adipositas
Brede, S., Lehnert, H., & Schmid, S. M. (2018) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0038-1654052
Links Between Glucocorticoid Responsiveness and Obesity
Henry, B. A., & Clarke, I. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813146-6.00023-0
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Glucocorticoid Action in the Mediobasal Hypothalamus Regulates Glucose Production In Vivo
Beaulieu-Bayne, E. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-eahb-a894
Farr, S. (2017) · TSpace (University of Toronto)
食後ホルモンインスリン・GLP-1の求心性迷走神経を介した摂食・糖代謝調節
岩﨑, 有., & 俊彦, 矢. (2021) · 自律神経 · doi:10.32272/ans.58.1_105
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Short-chain fatty acids: role in metabolic disorders
Fadieienko, G. D., & Gridnyev, O. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-2-55
Identification of a Dual-Action Small Molecule with Potent Anti-diabetic and Anti-obesity Activity
Wang, Y. (2019) · VTechWorks (Virginia Tech)
Pharmacological Evaluation of GPR40 Full Agonists in Metabolic Disease Models
上野, 光., ウエノ, ヒ., & Ueno, H. (2021) · Terrestrial Environment Research Center (University of Tsukuba)
Efeito da interleucina 17 na regulação hipotalâmica da homeostase energética
Nogueira, G. A. S. (2019) · doi:10.47749/t/unicamp.2019.1157283
Research Progress of Liraglutide in Improving Obesity
邢, 国. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111814
Farinha da casca de maracujá (Passiflora edulis): efeitos no tratamento e na prevenção da obesidade
Lima, G. C. (2015) · doi:10.47749/t/unicamp.2015.962141 · Cited by 2
The Effect of High-Intensity Interval Training on GLP-1, Appetite, and Weight in Obese Rats
Sepehri, H., Nemati, J., Jahromi, M. K., Eskandari, M. H., & Daryanoosh, F. (2021) · مجله علمی پزشکی جندی شاپور · doi:10.32598/jsmj.20.3.1975 · Cited by 1
GLP-1R Activation by Liraglutide Promotes Breast Cancer Through NOX4/ROS/VEGF PathwayPreprint
Liu, Z., Duan, X., Yuan, M., Yu, J. Y., Hu, X., Han, X., Lan, L., Liu, B., Wang, Y., & Qin, J. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3977559
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Obesity medication lorcaserin requires brainstem GLP-1 neurons to reduce food intake in micePreprint
Wagner, S., Brierley, D. I., Leeson-Payne, A. T. S., Jiang, W., Chianese, R., Lam, B., Dowsett, G. K. C., Cristiano, C., Lyons, D., Reimann, F. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.06.490598
“Consistent with the brain being the master coordinator of energy homeostasis, recent research indicates that the sites of action for the food intake suppressive effects of the 5-HT2CR agonist lorcaserin, GLP-1R agonists, and MC4R agonists reside within the CNS (1-8).”
BackgroundRickie, Kartinah, N. T., Siagian, M., Ibrahim, N., & Anggraini, S. (2022) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v28i2.2346
Pharmacotherapy for Weight Loss
Lutz, T. A., & Asarian, L. (2017) · Routledge eBooks · doi:10.1201/9781315120171-14 · Cited by 1
Vettor, R., & Conci, S. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_14-1 · Cited by 1
Vettor, R., & Conci, S. (2019) · Endocrinology · doi:10.1007/978-3-319-46933-1_14 · Cited by 4
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Xu, K., Liu, L., Yin, J., He, Y., & Zhou, H. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0355
Lv, B., Xing, C., Zhao, H., Wang, D., Wang, X., & He, B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4195255
玉苏普江, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132396
Cywes, R., Kajee, H., Wellington, N., Cucuzzella, M. T., Riley, K., Isaacs, D. M., Pataguana, N., Lake, I., Rauch, L., McKelvey, S., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821617-0.00010-3
Choice of Therapy in Obese Type 2 Diabetes
Jyotsna, V., & Deshmukh, S. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_2_22
Schirmer, M., Brandt, S., Zorn, S., & Wabitsch, M. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2079-9133 · Cited by 1
“[25] Secher A, Jelsing J, Baquero AF et al.”
Alhusayni, K. M., Aljuaid, A. M., Alkhammash, A. M., Alzahrani, S. A., Alorabi, A. K., Alotaibi, Y. B., Alhumaidi, N. T., Alharbi, W. K., Harbi, G. A., & Alzahrani, I. (2023) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2023.11735
“However, the satiation/satiety circuit that regulates food intake and body weight also involves GLP-1, which is generated in the brain [1].”
BackgroundInkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Relação entre a composição corporal e indicadores metabólicos com a actimetria do sono no adulto
Machado, L. A. M. W. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2023.tde-10112023-163029
Therapies in Disorders of Lipid Metabolism and Obesity
Akuffo Quarde, M. D. (2023) · Wiley eBooks · doi:10.1002/9781119863564.ch7
Yamada, S., & Monai, H. (2023) · doi:10.3791/65902-v
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Liraglutide and sibutramine: similarities and differences in pharmacotherapy of obesity
Romantsova, T. I. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-117-131
Konservative Adipositastherapie
Kretschmer, A. C., Arjune, S., & Hanßen, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01160-6
Review of pharmacological treatment registered for obesity in Poland
Wyrwał, J., Nowak, K., Olejarz, Z., Drygała, Z., Zielińska, Z., Słowik, M., Nowak, K., Nieć, M., Gierlach, K., & Krasuska, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.56.004
GLP1R Agonists Activate Human POMC NeuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Chen, J., Alcaino, C., Macarelli, V., Mali, I. D., Gribble, F. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855485
Yu, W., Liao, Y.-N., Yang, T.-H., Yang, C.-W., Kao, T., Lee, P.-W., Hsu, C.-Y., Huang, J.-L., Huang, Y., & Chen, H. (2024) · Healthcare · doi:10.3390/healthcare12131279 · Cited by 1
“Although the PS-based models balanced these differences, larger randomized controlled trials are necessary to confirm the true efficacy of LA on obesity, as well as its potential side effects.”
MethodMeyhöfer, S. M., Blüher, M., & Aberle, J. (2024) · Springer eBooks · doi:10.1007/978-3-662-58895-6_42
Mirasierra, M., Fernández-Pérez, A., Lizarbe, B., Keiran, N., Ruíz-Cañas, L., Casarejos, M. J., Cerdán, S., Vendrell, J. J., Fernández‐Veledo, S., & Vallejo, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05384-z
“…differences in the expression of the receptors for leptin, ghrelin (GHSR), adenosine A1 [53 ], α-MSH MC4R, glucagon-like peptide 1 (GLP1R) [ 54] or erythropoietin (EpoR) [ 55], but the expression of the α-MSH receptor MC3R [ 56, 57] was higher in Alx3 -defi - cient than in control animals…”
BackgroundModder, M., Coomans, C. P., Saaltink, D., Tersteeg, M. M. H., Hoogduin, J., Scholten, L., Pronk, A. C. M., Lalai, R. A., Boelen, A., Kalsbeek, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70639-5
“In addition to leptin, recent studies demonstrated that the appetite-inducing hormone ghrelin 36,37 and possibly also glucagon-like peptide 1 (GLP-1) 38,39 are transported by tanycytes.”
BackgroundAbramov, V. V., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2407-03
Bonner, C., Saponaro, C., Imbernón, M., Louvet, I., Deligia, E., Chen, S., Davies, I., Acosta-Montalvo, A., Moreno-Lopez, M., Wemelle, E., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5544620/v1
Alhamedi, N. M. (2025) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2025.6104 · Cited by 1
“…effects may be linked to the activation of both central and peripheral GLP-1 receptors and could arise from direct or indirect interactions with the central nervous system, activation of afferent parasympathetic pathways or effects on brain regions unprotected by the blood-brain barrier [8-19].”
Witte, A. V., & Sacher, J. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.02.027
Modder, M., Tomás, A., Afkir, S., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., van Eenige, R., Rensen, P. C. N., Jones, B. J., & Kooijman, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16374
“42 – 46 Furthermore, GLP-1 receptors in the ventromedial nucleus of the hypothalamus are primarily responsible for regulating adipose tissue thermogenesis via the sympathetic nervous system.”
Regulation of food intake in teleost fish
Soengas, J. L., Conde‐Sieira, M., & Blanco, A. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90873-3.00016-6 · Cited by 5
Preclinical Models for Gastrointestinal Disease and Associated Conditions
Fabris, F. M., Pinto, B. G., Júnior, G. D. F., Melo, R. B., Ferraz, C. P. M., & de Azevedo, O. G. R. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1007515
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Being Overweight: Impact on Disease Conditions
Shanmugham, D., Kabilan, V. R., Nagarajan, P., Gayathiri, E., & Kannan, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-32047-7_38-1
Diet context gates AgRP neuron involvement in Semaglutide-induced weight lossPreprint
d’Ávila, M., Collado‐Perez, R., Liu, Z., & Horváth, T. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.13.664597
Liraglutide Increases Gastric Fundus Tonus and Reduces Food Intake in Type 2 Diabetic Rats
Carrêlo, A. C. L., Martins, B. D., Seiça, R. M. F., Ribeiro, C., Matafome, P. N., & Silva, S. (2025) · Diabetology · doi:10.3390/diabetology6090096
Thermal challenge and food intake: Mutual regulatory mechanisms
Alpár, A. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00170 · Cited by 1
“A similar conduit applies for other blood-borne metabolites, which regulate food intake: ghrelin (Cabral et al., 2014) and glucagon-like peptide-1 (GLP-1) (Secher et al., 2014) are effectively transported from the arcuate nucleus towards the ventricular space.”
Choo, Y. N., Narayanan, R., & Subramaniyan, V. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107553 · Cited by 2
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Metabolic sexual dimorphism in hypothalamic Fezf1 neuron-specific BDNF knockout
da Silva, D. C., Zanesco, A. M., Rivera, F. V., Gallo-Ferraz, A. L., Simoes, M. R., Bombassaro, B., Sponton, C. H., & Velloso, L. A. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00770-z
Chan, Y.-C., Chuang, S., Wu, L.-C., Kuo, Y., Lian, Y.-Z., & Chen, Y. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.11.036 · Cited by 1
Wang, Y., Alkhalidy, H., Cao, X., Vaughan, R., RACHI, M. A. T. T., Xu, B., Kale, B. S., Silte, A. A., Rainville, J. R., Hodes, G. E., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110206
Araç, E., Solmaz, İ., & Alakuş, Ö. F. (2025) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1841074
Lerner, J. J., Schmid, L., Zorn, S., von Schnurbein, J., Siebert, R., & Wabitsch, M. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2606-2353
Obesity medications and acquired hypothalamic obesity in adults: A two-case experience
Lang, H., Dorand, M. F., Hassan, M., & Richards, J. R. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100246
“GLP-1Rs in the ARC stimulate POMC/CART while suppressing NPY/AgRP leading to reduced food intake [45].”
Sayed, M. S., Kamel, B., Shaban, N. S., Rath, S., Alhnfi, I. M., Abdelbar, S. M. M., & Ali, M. Y. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002069
Lecube, A., & Lopez-Cano, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00350-2
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Sobiński, A., Sadowska, A., Welkier, A., Miśkiewicz, J., Dudek, A., Pietrusińska, P., Moder, J., Dziewierz, A., Kwaśniewska, P., & Śliwa-Tytko, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4326
Yang, W., Yang, Z., Lu, S., Meng, L., Yang, F., Liu, H., & Wang, J. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07274-1
Bouchat, A., Papini, L., Schläpfer, J., Kulka, P., & Foll, C. L. (2026) · bioRxiv · doi:10.64898/2026.03.27.714441
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.